CACNA2D2
ENSG00000007402
Target class
Auxiliary transport protein
Chromosome
3
Approved drugs
6
Clinical candidates (approved and in development)
9
- Approved drugs
- 6
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- No
- Target name
- CACNA2D2
- Gene name
- Calcium voltage-gated channel auxiliary subunit alpha2delta 2
- Gene symbol
- CACNA2D2
- Protein name
- Voltage-dependent calcium channel subunit alpha-2/delta-2 (Voltage-gated calcium channel subunit alpha-2/delta-2) [Cleaved into: Voltage-dependent calcium channel subunit alpha-2-2; Voltage-dependent calcium channel subunit delta-2]
- KIAA0558
- alpha2delta-2
- Gene biotype
- Protein coding
- Gene family
- Calcium voltage-gated channel auxiliary alpha2delta subunits
- Target class
- Auxiliary transport protein
- Target type
- Human gene
- Tissues expressed in
- 47
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 41.88
- Tissue specificity (Gini)
- 0.564
- Tissue specificity (tau)
- 0.877
- KEGG gene identifiers
- hsa:9254
- Protein interaction confidence
- 0.870375
- Protein interaction partners
- 24
- R-HSA-112308
- R-HSA-400042
- R-HSA-422356
- R-HSA-5576892
- R-HSA-5576893
- R-HSA-9662360
- End position
- 50504244
- Start position
- 50362613
- Chromosome
- 3
- Strand
- Reverse
- Membrane
- Single-pass type I membrane protein . Note=Colocalizes with CACNA1A in lipid raft fractions. .
- Cytosol
- Flagellar centriole
- Mid piece
- Plasma membrane
- Tissue specificity (tau)
- 0.876696
- Expression inequality (Gini)
- 0.564299
Expression in transcripts per million
- Brain - Cerebellum
- 41.88
- Lung
- 33.24
- Brain - Cerebellar Hemisphere
- 33.16
- Pituitary
- 16.23
- Brain - Hypothalamus
- 15.22
Expression in transcripts per million
- Brain - Cerebellum41.88
- Lung33.24
- Brain - Cerebellar Hemisphere33.16
- Pituitary16.23
- Brain - Hypothalamus15.22
- Testis14.76
- Brain - Nucleus accumbens (basal ganglia)11.44
- Brain - Caudate (basal ganglia)9.06
- Heart - Atrial Appendage8.65
- Brain - Frontal Cortex (BA9)7.58
- Brain - Cortex7.26
- Brain - Putamen (basal ganglia)6.41
- Brain - Substantia nigra5.68
- Ovary5.44
- Cervix - Endocervix4.96
- Brain - Anterior cingulate cortex (BA24)4.96
- Uterus4.84
- Prostate4.71
- Stomach4.58
- Thyroid4.54
- Artery - Aorta4.51
- Cervix - Ectocervix3.88
- Fallopian Tube3.49
- Kidney - Cortex3.23
- Skin - Sun Exposed (Lower leg)3.1
And 29 more, listed on the interactive page.
Cellular components
- GO:0005886
Related records
Trials (1,015)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- [S,S]-Reboxetine Add-On Trial
- 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
- A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
- A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects
Drugs (12)
- Atagabalin Voltage-gated calcium channel modulator
- Bepridil Voltage-gated calcium channel blocker
- Bepridil hydrochloride Voltage-gated calcium channel blocker
- Gabapentin Voltage-gated calcium channel modulator
- Gabapentin enacarbil Voltage-gated calcium channel modulator
- Imagabalin Voltage-gated calcium channel modulator
- Mirogabalin Voltage-gated calcium channel alpha2/delta subunit 2 modulator
- Phloroglucinol Voltage-gated calcium channel blocker
- Pregabalin Voltage-gated calcium channel modulator
- Suloctidil Voltage-gated calcium channel blocker
- Terodiline Voltage-gated calcium channel blocker
- Terodiline hydrochloride Voltage-gated calcium channel blocker